Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

A novel RNA variant of human concentrative nucleoside transporter 1 (hCNT1) that is a potential cancer biomarker.

Wang C, Buolamwini JK.

Exp Hematol Oncol. 2019 Aug 22;8:18. doi: 10.1186/s40164-019-0144-y. eCollection 2019.

2.

QSAR Studies of New Pyrido[3,4-b]indole Derivatives as Inhibitors of Colon and Pancreatic Cancer Cell Proliferation.

Deokar H, Deokar M, Wang W, Zhang R, Buolamwini JK.

Med Chem Res. 2018 Dec;27(11-12):2466-2481. doi: 10.1007/s00044-018-2250-5. Epub 2018 Oct 3.

3.

Inhibiting β-Catenin by β-Carboline-Type MDM2 Inhibitor for Pancreatic Cancer Therapy.

Qin JJ, Wang W, Li X, Deokar H, Buolamwini JK, Zhang R.

Front Pharmacol. 2018 Jan 17;9:5. doi: 10.3389/fphar.2018.00005. eCollection 2018.

4.

Synthesis, Biological Evaluation and Modeling Studies of New Pyrido[3,4-b]indole Derivatives as Broad-Spectrum Potent Anticancer Agents.

Patil SA, Addo JK, Deokar H, Sun S, Wang J, Li W, Suttle DP, Wang W, Zhang R, Buolamwini JK.

Drug Des. 2017 Mar;6(1). pii: 143. doi: 10.4172/2169-0138.1000143. Epub 2017 Mar 1.

5.

Homology Modeling of Human Concentrative Nucleoside Transporters (hCNTs) and Validation by Virtual Screening and Experimental Testing to Identify Novel hCNT1 Inhibitors.

Kumar Deokar H, Barch HP, Buolamwini JK.

Drug Des. 2017 Mar;6(1). pii: 146. doi: 10.4172/2169-0138.1000146. Epub 2017 Mar 31.

6.

Dilazep analogues for the study of equilibrative nucleoside transporters 1 and 2 (ENT1 and ENT2).

Playa H, Lewis TA, Ting A, Suh BC, Muñoz B, Matuza R, Passer BJ, Schreiber SL, Buolamwini JK.

Bioorg Med Chem Lett. 2014 Dec 15;24(24):5801-5804. doi: 10.1016/j.bmcl.2014.10.026. Epub 2014 Oct 28.

7.

Development and validation of a rapid HPLC method for quantitation of SP-141, a novel pyrido[b]indole anticancer agent, and an initial pharmacokinetic study in mice.

Nag S, Qin JJ, Voruganti S, Wang MH, Sharma H, Patil S, Buolamwini JK, Wang W, Zhang R.

Biomed Chromatogr. 2015 May;29(5):654-63. doi: 10.1002/bmc.3327. Epub 2014 Oct 8.

8.

The pyrido[b]indole MDM2 inhibitor SP-141 exerts potent therapeutic effects in breast cancer models.

Wang W, Qin JJ, Voruganti S, Srivenugopal KS, Nag S, Patil S, Sharma H, Wang MH, Wang H, Buolamwini JK, Zhang R.

Nat Commun. 2014 Oct 1;5:5086. doi: 10.1038/ncomms6086.

9.

A quantitative LC-MS/MS method for determination of SP-141, a novel pyrido[b]indole anticancer agent, and its application to a mouse PK study.

Nag S, Qin JJ, Patil S, Deokar H, Buolamwini JK, Wang W, Zhang R.

J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Oct 15;969:235-240. doi: 10.1016/j.jchromb.2014.08.030. Epub 2014 Aug 28.

10.

Identification of a new class of MDM2 inhibitor that inhibits growth of orthotopic pancreatic tumors in mice.

Wang W, Qin JJ, Voruganti S, Wang MH, Sharma H, Patil S, Zhou J, Wang H, Mukhopadhyay D, Buolamwini JK, Zhang R.

Gastroenterology. 2014 Oct;147(4):893-902.e2. doi: 10.1053/j.gastro.2014.07.001. Epub 2014 Jul 10.

11.

Impact of resistance mutations on inhibitor binding to HIV-1 integrase.

Chen Q, Buolamwini JK, Smith JC, Li A, Xu Q, Cheng X, Wei D.

J Chem Inf Model. 2013 Dec 23;53(12):3297-307. doi: 10.1021/ci400537n. Epub 2013 Nov 21.

PMID:
24205814
12.

Synthesis, docking, and biological studies of phenanthrene β-diketo acids as novel HIV-1 integrase inhibitors.

Sharma H, Sanchez TW, Neamati N, Detorio M, Schinazi RF, Cheng X, Buolamwini JK.

Bioorg Med Chem Lett. 2013 Nov 15;23(22):6146-51. doi: 10.1016/j.bmcl.2013.09.009. Epub 2013 Sep 11.

13.
14.

Chemoprevention activity of dipyridamole in the MMTV-PyMT transgenic mouse model of breast cancer.

Wang C, Schwab LP, Fan M, Seagroves TN, Buolamwini JK.

Cancer Prev Res (Phila). 2013 May;6(5):437-47. doi: 10.1158/1940-6207.CAPR-12-0345. Epub 2013 Feb 27.

15.

Inhibition of gastric tumor growth by a novel Hsp90 inhibitor.

Lu C, Liu D, Jin J, Deokar H, Zhang Y, Buolamwini JK, Yu X, Yan C, Chen X.

Biochem Pharmacol. 2013 May 1;85(9):1246-56. doi: 10.1016/j.bcp.2013.02.003. Epub 2013 Feb 13.

16.

JKA97, a novel benzylidene analog of harmine, exerts anti-cancer effects by inducing G1 arrest, apoptosis, and p53-independent up-regulation of p21.

Yang X, Wang W, Qin JJ, Wang MH, Sharma H, Buolamwini JK, Wang H, Zhang R.

PLoS One. 2012;7(4):e34303. doi: 10.1371/journal.pone.0034303. Epub 2012 Apr 27.

17.

Homology model-guided 3D-QSAR studies of HIV-1 integrase inhibitors.

Sharma H, Cheng X, Buolamwini JK.

J Chem Inf Model. 2012 Feb 27;52(2):515-44. doi: 10.1021/ci200485a. Epub 2012 Feb 7.

PMID:
22256860
19.

Synthesis, biological evaluation and 3D-QSAR studies of 3-keto salicylic acid chalcones and related amides as novel HIV-1 integrase inhibitors.

Sharma H, Patil S, Sanchez TW, Neamati N, Schinazi RF, Buolamwini JK.

Bioorg Med Chem. 2011 Mar 15;19(6):2030-45. doi: 10.1016/j.bmc.2011.01.047. Epub 2011 Mar 1.

20.

A small-molecule inhibitor of MDMX activates p53 and induces apoptosis.

Wang H, Ma X, Ren S, Buolamwini JK, Yan C.

Mol Cancer Ther. 2011 Jan;10(1):69-79. doi: 10.1158/1535-7163.MCT-10-0581. Epub 2010 Nov 12.

21.

Identification of the ENT1 antagonists dipyridamole and dilazep as amplifiers of oncolytic herpes simplex virus-1 replication.

Passer BJ, Cheema T, Zhou B, Wakimoto H, Zaupa C, Razmjoo M, Sarte J, Wu S, Wu CL, Noah JW, Li Q, Buolamwini JK, Yen Y, Rabkin SD, Martuza RL.

Cancer Res. 2010 May 15;70(10):3890-5. doi: 10.1158/0008-5472.CAN-10-0155. Epub 2010 Apr 27.

23.

Synthesis and biological evaluation of phloridzin analogs as human concentrative nucleoside transporter 3 (hCNT3) inhibitors.

Gupte A, Buolamwini JK.

Bioorg Med Chem Lett. 2009 Feb 1;19(3):917-21. doi: 10.1016/j.bmcl.2008.11.112. Epub 2008 Dec 6.

PMID:
19097778
24.

CoMFA and CoMSIA 3D-QSAR studies on S(6)-(4-nitrobenzyl)mercaptopurine riboside (NBMPR) analogs as inhibitors of human equilibrative nucleoside transporter 1 (hENT1).

Gupte A, Buolamwini JK.

Bioorg Med Chem Lett. 2009 Jan 15;19(2):314-8. doi: 10.1016/j.bmcl.2008.11.092. Epub 2008 Nov 27.

PMID:
19091561
25.

Quantitative structure-activity relationship studies on nitrofuranyl anti-tubercular agents.

Hevener KE, Ball DM, Buolamwini JK, Lee RE.

Bioorg Med Chem. 2008 Sep 1;16(17):8042-53. doi: 10.1016/j.bmc.2008.07.070. Epub 2008 Jul 29.

26.

Constrained NBMPR analogue synthesis, pharmacophore mapping and 3D-QSAR modeling of equilibrative nucleoside transporter 1 (ENT1) inhibitory activity.

Zhu Z, Buolamwini JK.

Bioorg Med Chem. 2008 Apr 1;16(7):3848-65. doi: 10.1016/j.bmc.2008.01.044. Epub 2008 Jan 30.

27.

Anti-cancer effects of JKA97 are associated with its induction of cell apoptosis via a Bax-dependent and p53-independent pathway.

Luo W, Liu J, Li J, Zhang D, Liu M, Addo JK, Patil S, Zhang L, Yu J, Buolamwini JK, Chen J, Huang C.

J Biol Chem. 2008 Mar 28;283(13):8624-33. doi: 10.1074/jbc.M707860200. Epub 2008 Jan 23. Erratum in: J Biol Chem. 2012 Jul 6;287(28):23850.

28.
30.
31.

Synthesis and biological evaluation of novel 5(H)-phenanthridin-6-ones, 5(H)-phenanthridin-6-one diketo acid, and polycyclic aromatic diketo acid analogs as new HIV-1 integrase inhibitors.

Patil S, Kamath S, Sanchez T, Neamati N, Schinazi RF, Buolamwini JK.

Bioorg Med Chem. 2007 Feb 1;15(3):1212-28. Epub 2006 Nov 16.

PMID:
17158051
32.

Targeting EGFR and HER-2 receptor tyrosine kinases for cancer drug discovery and development.

Kamath S, Buolamwini JK.

Med Res Rev. 2006 Sep;26(5):569-94. Review.

PMID:
16788977
33.

6-Benzylthioinosine analogues: promising anti-toxoplasmic agents as inhibitors of the mammalian nucleoside transporter ENT1 (es).

Gupte A, Buolamwini JK, Yadav V, Chu CK, Naguib FN, el Kouni MH.

Biochem Pharmacol. 2005 Dec 19;71(1-2):69-73. Epub 2005 Nov 23.

PMID:
16310172
34.

Molecule-kinase interaction map.

Buolamwini JK, Kamath S.

Nat Biotechnol. 2005 Nov;23(11):1346; author reply 1346-8. No abstract available.

PMID:
16273056
36.

Identification of N10-substituted phenoxazines as potent and specific inhibitors of Akt signaling.

Thimmaiah KN, Easton JB, Germain GS, Morton CL, Kamath S, Buolamwini JK, Houghton PJ.

J Biol Chem. 2005 Sep 9;280(36):31924-35. Epub 2005 Jul 11.

37.

Small molecule antagonists of the MDM2 oncoprotein as anticancer agents.

Buolamwini JK, Addo J, Kamath S, Patil S, Mason D, Ores M.

Curr Cancer Drug Targets. 2005 Feb;5(1):57-68. Review.

PMID:
15720190
39.

Novel halogenated nitrobenzylthioinosine analogs as es nucleoside transporter inhibitors.

Gupte A, Buolamwini JK.

Bioorg Med Chem Lett. 2004 May 3;14(9):2257-60.

PMID:
15081020
40.

Application of CoMFA and CoMSIA 3D-QSAR and docking studies in optimization of mercaptobenzenesulfonamides as HIV-1 integrase inhibitors.

Kuo CL, Assefa H, Kamath S, Brzozowski Z, Slawinski J, Saczewski F, Buolamwini JK, Neamati N.

J Med Chem. 2004 Jan 15;47(2):385-99.

PMID:
14711310
41.
42.
43.

Overview of novel anticancer drug targets.

Buolamwini JK, Assefa H.

Methods Mol Med. 2003;85:3-28. Review. No abstract available.

PMID:
12710193
45.

Antisense anticancer oligonucleotide therapeutics.

Wang H, Prasad G, Buolamwini JK, Zhang R.

Curr Cancer Drug Targets. 2001 Nov;1(3):177-96. Review.

PMID:
12188878
47.

Molecular targets in cancer drug discovery: cell-based profiling.

Weinstein JN, Buolamwini JK.

Curr Pharm Des. 2000 Mar;6(4):473-83. Review.

PMID:
10788592
48.

Cell cycle molecular targets in novel anticancer drug discovery.

Buolamwini JK.

Curr Pharm Des. 2000 Mar;6(4):379-92. Review.

PMID:
10788588
49.

Novel anticancer drug discovery.

Buolamwini JK.

Curr Opin Chem Biol. 1999 Aug;3(4):500-9. Review.

PMID:
10419854
50.

A protein expression database for the molecular pharmacology of cancer.

Myers TG, Anderson NL, Waltham M, Li G, Buolamwini JK, Scudiero DA, Paull KD, Sausville EA, Weinstein JN.

Electrophoresis. 1997 Mar-Apr;18(3-4):647-53.

PMID:
9150955

Supplemental Content

Loading ...
Support Center